The mission of Pixium Vision (Euronext: ALPIX, FR0011950641) is to create a world of bionic vision for those who have lost their sight. Age-related macular degeneration (AMD) is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates of 196 million people worldwide living with AMD and expected rapid growth due to ageing population. Around 1,000 new patients are diagnosed every day in Europe and U.S. There are two forms of advanced AMD: the wet form, where treatment like anti-VEGF injections slows down the disease progression, and the dry form that is most frequent, where there is currently no curative treatment available. More than 5 million patients are afflicted with advanced dry AMD, also referred to as Geographic Atrophy.
Pixium Vision has addressed this important medical and societal need by developing PRIMA System, which is designed to restore sight in patients blinded by retinal dystrophies especially atrophic dry AMD. It features a miniaturized and totally wireless sub-retinal implant and augmented reality glasses. The PRIMA implant is placed under the retina via a minimally invasive surgical procedure, it acts like an array of tiny solar panels powered by pulsed near-infrared light emitted from a miniature projector transmitting images captured on a mini camera. The camera and projector technologies are integrated into augmented reality glasses, which together with the PRIMA implant, make the PRIMA System.
Pixium Vision is currently conducting in France and in the United States, two feasibility clinical trials with the PRIMA System, for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of AMD Recruitment has been completed in France with 12 months’ interim results that have recently been published
Pixium Vision intends to commercialize the PRIMA System by first targeting Dry-AMD and secondly other retinal dystrophies like Retinitis Pigmentosa (RP).
Pixium Vision, with its novel breakthrough PRIMA System comprising a miniaturized and wireless sub-retinal next generation implant, addressing a significant unmet need where no treatment is available to date, is in a unique position to significantly contribute to the restoration in the form of artificial vision to people who have lost sight, in order to enable them to live more autonomously with an improved quality of life.
Pixium Vision successfully completed its IPO in June 2014, raising €39.5M. In total, the company raised €90,2M since its creation.
More information on www.pixium-vision.com
GenSight Biologics S.A. (Euronext: SIGHT, FR0013183985) is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases.
GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), has been submitted for marketing approval in Europe for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness, and in phase III prior to filing the BLA in the United States (Biologics License Application [BLA]).
The company has also announced the first case report of a blind patient treated with the optogenetics GS030 treatment, published in Nature Medicine* in May 2021, first peer-reviewed publication to document partial visual recovery in a blind patient with late-stage inherited retinal disease. GS030 is currently in PIONEER Phase I/II clinical trial in Europe and the US. Interim results are expected by end 2021.
Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
GenSight Biologics successfully completed its IPO in July 2016, raising €45M. Overall, the company has raised €197M since its creation.
More information on www.gensight-biologics.com
*: Partial recovery of visual function in a blind patient after optogenetic therapy. Sahel J.A. et al., Nature Medicine, May 2021
TISSIUM is a privately-owned medtech company based in Paris, France and Boston, USA that is dedicated to the development and commercialization of a unique biopolymer platform to address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of solutions that leverage its proprietary family of fully biosynthetic, biomorphic and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including nerve repair, hernia and cardiovascular. Each product is designed to enhance the tissue reconstruction process in a unique way. The company also develops delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
The company has raised €120m in equity since inception.
For more information, please visit: www.TISSIUM.com and @TISSIUMtech.
Prophesee is the inventor of the world’s most advanced neuromorphic vision systems. Mimicking the human eye and brain, Prophesee’s patented event-based approach perceives only the most relevant motion information thanks to intelligent and independent pixels, thus drastically reducing the power, latency and data processing requirements of traditional systems.
The sensors and AI algorithms Metavision® of Prophesee open new fields of possibilities in many areas such as autonomous vehicles, industrial automation, the Internet of Things, mobile, security and surveillance and augmented reality. The solutions developed by Prophesee improve security, efficiency and customer experience and have numerous applications.
Prophesee was created in Paris in 2014 within the iBionext start-up studio by Ryad Benosman, Bernard Gilly, Christoph Posch and Luca Verre. This quartet has a solid experience in biomimicry and natural computation, microelectronics design, entrepreneurship and business development.
Headquartered in Paris as part of the Passage de l’Innovation with offices in Japan and the United States, Prophesee brings together 100 visionary engineers, holds more than 50 international patents and is backed by world-renowned investors including 360 Capital Partners, European Investment Bank, iBionext, Intel Capital, Renault-Nissan, Robert Bosch Ventures, Sinovation, Sony, Supernova Invest, Will Semiconductor, Xiaomi.
Prophesee has raised $94M since its creation in 2014.
More information on www.prophesee.ai
Founded in 2016 by Prof. Alain Prochiantz and Bernard Gilly, BrainEver is a biotechnology company specialized in the discovery and development of innovative treatments for neurodegenerative diseases.
BrainEver harnesses the intrinsic properties of homeoproteins, a family of transcription factors that are essential during embryonic and postnatal development. Recent studies have also demonstrated that homeoproteins play a key role in the maintenance and survival of specific neuronal populations in adults. An important property of homeoproteins is their ability to penetrate cells, with privileged access to cytoplasmic and nuclear compartments. Therefore, they do not require any transportation system to reach the target cells.
BrainEver has raised 21M € from iBionext, Bpifrance and Turenne Capital, in 2017. The FDA has granted orphan drug designation to its product BE102 for the treatment of amyotrophic lateral sclerosis (ALS). After the completion of the manufacturing process, BrainEver is now finalizing the preclinical phase before entering into clinics with a first in human study in ALS.
Created in 2015, Chronolife is a MedTech and a service operator specialized in digital health that develops solutions for the remote monitoring and prediction of patients’ health status. In the form of connected medical garments, Chronolife’s technology allows the monitoring of multiple physiological parameters.
Chronolife proposes 2 types of offers and services:
The solutions developed by Chronolife ensure a continuous, accurate and real-time monitoring of patients by promoting adherence to the device, helping to anticipate the worsening of the health status, and ensuring a better quality of life for patients. Ultimately, they allow a reduction of the associated healthcare costs.
Total raised amount: €11,7M with iBionext, Aesio, Celeste and F&F
Founded in 2016, Tilak Healthcare is developing a new form of digital medicine: medical mobile video games that enable remote monitoring of chronic disease progression in patients. The team, composed of medical experts and video game specialists, aims to improve compliance in patients requiring regular monitoring by offering fun applications that combine video games and medical tests.
The company’s first game – OdySight – allows patients with chronic diseases affecting the macula (maculopathies) to take visual acuity tests at home. The results are instantly shared with their ophthalmologist and in case of sudden vision loss, an emergency appointment is scheduled. As the number of ophthalmologists in France remains low and appointments are sometimes difficult to make, OdySight offers a safe, practical, and innovative alternative.
The OdySight app was clinically validated at the Quinze-Vingts Hospital in 2018, and is now used by 350 doctors and more than 3500 patients in France. In 2021, the solution was deployed in two new countries (the United States and Spain) and is planned to be made available in many European countries.
After successfully launching in the field of ophthalmology, Tilak Healthcare now aims to become a pioneer in the development of digital medicine and is exploring new areas of focus, including psychiatry and neurology.
More information at https://tilakhealthcare.com/ and https://odysight.app/
GrAI Matter Labs (GML) driving AI at The Speed of Life
GML has created the world’s first edge AI processor leveraging bio-inspired techniques to enable ultra-low latency at low power for machine vision and sensor analytics. Using GML’ processors allows edge devices to navigate our world with life-like response times, safety and convenience.
GML’ edge AI processors create life ready possibilities for applications including industrial automation, autonomous navigation, visual inspection, drones, surveillance, AR/VR, smart cities, cognitive virtual assistants and many others.
These edge processors are based on breakthrough neuromorphic research carried out at the Vision Institute (UPMC) in Paris during the past 20 years. The new bio-inspired approach to computation leverages the concept of sparsity, or processing only changes that matter, to overcome the challenges of classical computing architectures (von Neumann bottleneck).
GrAI Matter Labs was created in 2016. Today the international team of engineering professionals and AI experts work across the three company offices in France, the Netherlands and the United States.
Since 2016 GrAI Matter Labs has raised $29M, supported by iBionext (lead investor), 360 Capital Partners, 3T Finance and Celeste Management.
For more information visit www.graimatterlabs.ai
Founded in 2018, T-Heart is a breakthrough company developing an innovative and differentiated transcatheter heart Valve replacement system for the treatment of severe tricuspid regurgitation (TR).
TR is a progressive condition in which blood leaks backwards through the Tricuspid valve, potentially leading to heart failure and death.
T-Heart’s patented innovation addresses the tricuspid specific anatomical challenges through a one-step simple procedure yet managing the right ventricular load using a physiologically sized valve.
T-Heart’s minimally invasive technology addresses this unmet clinical need, and a market potential evaluated at $3bn per annum.
Financed by iBionext Growth Fund